dipyridamole has been researched along with Fibrodysplasia Ossificans Progressiva in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cappato, S | 1 |
| Tonachini, L | 1 |
| Giacopelli, F | 1 |
| Tirone, M | 1 |
| Galietta, LJ | 1 |
| Sormani, M | 1 |
| Giovenzana, A | 1 |
| Spinelli, AE | 1 |
| Canciani, B | 1 |
| Brunelli, S | 1 |
| Ravazzolo, R | 1 |
| Bocciardi, R | 1 |
1 other study available for dipyridamole and Fibrodysplasia Ossificans Progressiva
| Article | Year |
|---|---|
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.
Topics: Activin Receptors, Type I; Animals; Biomarkers; Bone Morphogenetic Proteins; Calcium; Cell Different | 2016 |